- Home
- ACRS vs FBYD Comparison
ACRS vs FBYD Comparison
Compare ACRS & FBYD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- FBYD
- Stock Information
- Founded
- ACRS 2012
- FBYD 2021
- Country
- ACRS United States
- FBYD United States
- Employees
- ACRS N/A
- FBYD N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- FBYD
- Sector
- ACRS Health Care
- FBYD
- Exchange
- ACRS Nasdaq
- FBYD Nasdaq
- Market Cap
- ACRS 132.0M
- FBYD 120.8M
- IPO Year
- ACRS 2015
- FBYD N/A
- Fundamental
- Price
- ACRS $4.32
- FBYD $9.41
- Analyst Decision
- ACRS Buy
- FBYD
- Analyst Count
- ACRS 6
- FBYD 0
- Target Price
- ACRS $7.20
- FBYD N/A
- AVG Volume (30 Days)
- ACRS 6.0M
- FBYD 16.1K
- Earning Date
- ACRS 11-06-2024
- FBYD 11-14-2024
- Dividend Yield
- ACRS N/A
- FBYD N/A
- EPS Growth
- ACRS N/A
- FBYD N/A
- EPS
- ACRS N/A
- FBYD N/A
- Revenue
- ACRS $27,079,000.00
- FBYD $7,042,000.00
- Revenue This Year
- ACRS N/A
- FBYD N/A
- Revenue Next Year
- ACRS N/A
- FBYD N/A
- P/E Ratio
- ACRS N/A
- FBYD N/A
- Revenue Growth
- ACRS 26.35
- FBYD N/A
- 52 Week Low
- ACRS $0.77
- FBYD $7.02
- 52 Week High
- ACRS $5.17
- FBYD $12.93
- Technical
- Relative Strength Index (RSI)
- ACRS 74.71
- FBYD 48.58
- Support Level
- ACRS $3.67
- FBYD $8.51
- Resistance Level
- ACRS $5.17
- FBYD $9.87
- Average True Range (ATR)
- ACRS 0.47
- FBYD 0.63
- MACD
- ACRS 0.20
- FBYD 0.01
- Stochastic Oscillator
- ACRS 72.93
- FBYD 58.44
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
About FBYD Falcon's Beyond Global Inc.
Falcons Beyond Global Inc. is a Company that provides a full range of theme park design, master planning, and experiential technologies for customers in the entertainment and attraction industry through its Falcon's Creative Group reportable segment and develops and co-owns resort and theme park attractions through its Destinations Operations. The Company has five operating segments, Falcon's Creative Group, PDP, Sierra Parima, Falcon's Beyond Brands, and Destinations Operations, all of which are reportable segments. It earns the majority of the revenue from Falcon's Creative Group segment.